Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

被引：6

作者：

Shah, Jatin J. ^{[1
]}

Feng, Lei ^{[2
]}

Thomas, Sheeba K. ^{[3
]}

Weber, Donna ^{[3
]}

Wang, Michael ^{[4
]}

Manasanch, Elisabet E. ^{[3
]}

Mendoza, Kathleen ^{[3
]}

Orlowski, Robert Z. ^{[4
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

10.1182/blood.V126.23.1540.1540

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study
Iida, Shinsuke
Watanabe, Takashi
Matsumoto, Morio
Suzuki, Kenshi
Sunami, Kazutaka
Ishida, Tadao
Ando, Kiyoshi
Chou, Takaaki
Ozaki, Shuji
Taniwaki, Masafumi
Uike, Naokuni
Shibayama, Hirohiko
Hatake, Kiyohiko
Izutsu, Koji
Ishikawa, Takayuki
Shumiya, Yoshihisa
Tobinai, Kensei
CANCER SCIENCE, 2019, 110 (09) : 2924 - 2932
[22] Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study.
Rosenbaum, Cara Ann
Stephens, Leonor Ano
Kukreti, Vishal
Zonder, Jeffrey A.
Cole, Craig
Zimmerman, Todd M.
Reece, Donna Ellen
Berdeja, Jesus G.
Severson, Erica
Revethis, Andrea
Wolfe, Brittany
McDonnell, Kathryn
Nam, Jennifer
Griffith, Kent A.
Jakubowiak, Andrzej J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[23] Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.
Biran, Noa
Siegel, David Samuel DiCapua
Berdeja, Jesus G.
Raje, Noopur S.
Cornell, Robert F.
Alsina, Melissa
Kovacsovics, Tibor
Fang, Belle
Kimball, Amy
Landgren, Carl Ola
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[24] Daratumumab-Based Regimens with Prior Carfilzomib in Patients with Relapsed Refractory Multiple Myeloma (RRMM)
Tungesvik, Alexandre
Huang, Jessica
Sudalagunta, Praneeth
Dimaggio, Elizabeth
De Avila, Gabe
Tandon, Ankita
Nelson, Rebeccah
Olson, Laura
Tobon, Katherine
Shain, Kenneth
Brayer, Jason
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S327 - S328
[25] Relationship of Carfilzomib Dosing and Duration of Therapy (DOT) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
Harvey, R. Donald
Chen, Yaozhu J.
Lethen, Jan
Mahue, Maya
BLOOD, 2015, 126 (23)
[26] A Phase 1 Dose-Escalation Study of LH031, a Kinesin Spindle Protein Inhibitor, in Patients with Refractory/Resistance Multiple Myeloma
Xia, Zhongjun
Li, Su
Chen, Xiaoqin
Wang, Weida
Song, Yan
BLOOD, 2020, 136
[27] Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Shah, Jatin J.
Thomas, Sheeba K.
Weber, Donna M.
Wang, Michael
Alexanian, Raymond
Qazilbash, Muzaffar H.
Bashir, Qaiser
Parmar, Simrit
Shah, Nina
Popat, Uday R.
Orlowski, Robert Z.
BLOOD, 2012, 120 (21)
[28] Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
Fostier, Karel
De Becker, Ann
Schots, Rik
ONCOTARGETS AND THERAPY, 2012, 5 : 237 - 244
[29] Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design
Moreau, Philippe
Dimopoulos, Meletios A.
Yong, Kwee
Mikhael, Joseph
Risse, Marie-Laure
Asset, Gaelle
Martin, Thomas
FUTURE ONCOLOGY, 2020, 16 (02) : 4347 - 4358
[30] Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency
Badros, A. Z.
Vij, R.
Martin, T.
Zonder, J. A.
Wong, A. F.
Woo, T.
Boussina, K.
Wang, Z.
Niesvizky, R.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 →